Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Glenmark Pharmaceuticals
Large Cap•14,989 Employees•IPO 1999
Current Price
₹2225.80
108.2 (5.11%)Updated
Today's Range
₹2130.40
₹2240.00
₹2225.80
52 Week Range
52W Low₹1336.00
52W High₹2284.80
₹2225.80
Downside66.60%
Upside2.65%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹57,520.99 Cr
Market Cap
Total market value of companyP/E Ratio
53.82
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
5.75
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹37.72
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
6.67%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
19.40%
ROCE
Return on Capital Employed. >15% is goodNet Margin
6.47%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
6.16%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
4.60%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
0.62%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-23.50%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.28
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹313.60
Book Value
Net asset value per shareDividend Yield
0.12%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
46.60%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Glenmark exhibits a robust Return on Equity (ROE) of 15.8% and a strong Return on Capital Employed (ROCE) of 19.4%, signifying efficient capital utilization and effective operational efficiency for profit generation.
- •The company maintains a healthy financial structure with a low debt-to-equity ratio of 0.28, minimizing the risk of financial distress. This financial stability is crucial for sustained growth and investor confidence.
Weaknesses
3 points- •Glenmark's current Price-to-Earnings (P/E) ratio of 39.00 is relatively high compared to some industry peers, potentially suggesting an overvaluation. Investors should carefully consider this metric.
- •The company's latest quarterly profit variation shows a decline of -23.50%, indicating recent operational challenges. This inconsistency in profitability needs to be closely monitored by investors.
Opportunities
3 points- •The pharmaceutical industry is experiencing global expansion driven by increasing healthcare demand, new drug discoveries, and rising chronic disease prevalence, offering significant growth avenues for Glenmark.
- •Glenmark's current market capitalization of ₹51,950 Cr positions it as a mid-cap player, providing ample scope for market share expansion and growth within the competitive pharma sector.
Threats
3 points- •Glenmark faces intense competition from larger, well-established peers like Sun Pharma and Cipla, which possess greater market share and R&D capabilities, potentially limiting growth.
- •The pharmaceutical sector is highly susceptible to stringent regulatory changes, pricing pressures, and patent expirations, which could significantly impact Glenmark's revenue and profitability.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹2486.27 | +₹260.47 | +11.70% |
| R3 | ₹2376.67 | +₹150.87 | +6.78% |
| R2 | ₹2308.33 | +₹82.53 | +3.71% |
| R1 | ₹2267.07 | +₹41.27 | +1.85% |
| PIVOT | ₹2198.73 | -27.07 | -1.22% |
| CURRENT | ₹2225.80 | - | - |
| S1 | ₹1938.27 | -₹287.53 | -12.92% |
| S2 | ₹2047.87 | -₹177.93 | -7.99% |
| S3 | ₹2089.13 | -₹136.67 | -6.14% |
| S4 | ₹2157.47 | -₹68.33 | -3.07% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+220.7% vs avg
1.55M
(10 Mar 2026)Delivery %-13.7% vs avg
30.5%
(10 Mar 2026)Avg Volume (20D)20-day average
4.85L
(10 Feb - 10 Mar)Avg Delivery %Trend ↓
44.3%
(10 Feb - 10 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Laurus Labs Ltd
883.00 %
Highest Dividend Yield
Glaxosmithkline Pharmaceuticals Ltd
3.32 %
Peer Comparison
| Company Name |
|---|
 Abbott India Ltd |
 Ajanta Pharma Ltd |
 Alkem Laboratories Ltd |
 Aurobindo Pharma Ltd |
 Cohance Lifesciences Ltd |
 Gland Pharma Ltd |
 Glaxosmithkline Pharmaceuticals Ltd |
 Ipca Laboratories Ltd |
 J B Chemicals & Pharmaceuticals Ltd |
 Laurus Labs Ltd |
 Lupin Ltd |
 Mankind Pharma Ltd |
 Piramal Pharma Ltd |
 Sun Pharmaceutical Industries Ltd |
 Zydus Lifesciences Ltd |
About
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals is a global pharmaceutical company engaged in the development, manufacturing, and sale of a diverse range of pharmaceutical products. Their portfolio encompasses generic medications, specialty pharmaceuticals, and over-the-counter (OTC) drugs, distributed across major global markets including India, North America, Latin America, and Europe. The company’s manufacturing capabilities span various dosage forms, including complex injectables and biologics, oral solids and liquids, topical products, drops, and respiratory inhalers (MDI/DPI/nasal sprays).
Glenmark focuses on several key therapeutic areas, offering branded and generic formulations for dermatological conditions, respiratory illnesses, oncology treatments, cardiovascular diseases, diabetes, gynecological issues, gastroenterological problems, and anti-infective therapies. This broad therapeutic reach allows them to cater to a wide patient base and diverse healthcare needs.
A significant aspect of Glenmark's business strategy is its robust research and development (R&D) pipeline. The company is actively involved in the development of innovative new therapies, focusing primarily on oncology and immunology. Notable examples include ISB 2001, a trispecific antibody targeting multiple myeloma; ISB 1442, a bispecific antibody also targeting multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor for solid tumors. Furthermore, their pipeline features investigational treatments for autoimmune diseases, such as ISB 880 (an IL-1RAP antagonist) and ISB 830 (a telazorlimab OX40 antagonist), which are currently undergoing clinical trials.
Beyond its R&D efforts, Glenmark also markets established products, including Ryaltris, a nasal spray indicated for seasonal allergic rhinitis. This demonstrates a balanced approach, combining innovation with the commercialization of existing, effective therapies. The company's long history, established in 1977 and headquartered in Mumbai, India, provides a strong foundation for its continued growth and global presence within the pharmaceutical industry.
COMPANY FACTS - GLENMARK
Registered Address
Glenmark House, HDO Corporate Building, Wing - A, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri - E
Mumbai
MAHARASHTRA
IN
Tel: 912240189999
Website:https://glenmarkpharma.com/
Investor Relations:http://www.glenmarkpharma.com/investors/financial-result
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 14,989
IPO Date: 10/12/1999
MANAGEMENT - GLENMARK
Mr. Glenn Saldanha
Executive Chairman of the Board, Managing Director
Mr. V. S. Mani
Global Chief Financial Officer, Executive Director
Mr. Harish Kuber
Compliance Officer, Company Secretary
Mrs. Cherylann Pinto
Executive Director - Corporate Services
Mrs. Blanche Saldanha
Non-Executive Director
Mr. Dipankar Bhattacharjee
Non-Executive Independent Director
Mr. Rajesh Desai
Non-Executive Independent Director
Mrs. Vijayalakshmi Iyer
Non-Executive Independent Director
Ms. Sona Ramasastry
Non-Executive Independent Director
Investor Questions Answered
Glenmark Pharmaceuticals Ltd (GLENMARK) Stock FAQs
Get answers to the most common questions about Glenmark Pharmaceuticals Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Glenmark Pharmaceuticals Ltd (GLENMARK) is ₹2,225.8. Today, the stock has gained by ₹108.20 (5.11%), trading in a range of ₹2,130.4 to ₹2,240. The stock opened at ₹2,140 with a trading volume of 15,54,898 shares.
Glenmark Pharmaceuticals Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹57,520.99 crores, P/E ratio of 53.82, ROE of 6.67%, and ROCE of 19.40%. The dividend yield stands at 0.12%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Glenmark Pharmaceuticals Ltd (GLENMARK) is ₹2,284.8, while the 52-week low is ₹1,336. Currently trading at ₹2,225.8, the stock is 93.8% away from its 52-week low and 2.6% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Glenmark Pharmaceuticals Ltd stock at ₹2,225.8 depends on multiple factors. The stock is currently trading with a P/E ratio of 53.82 and P/B ratio of N/A. Today's performance shows a gain of 5.11%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Glenmark Pharmaceuticals Ltd offers a dividend yield of 0.12%, which means for every ₹100 invested at the current price of ₹2,225.8, you can expect to receive approximately ₹0.12 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Glenmark Pharmaceuticals Ltd's key financial metrics include: P/E Ratio: 53.82, P/B Ratio: N/A, ROE: 6.67%, ROCE: 19.40%, Dividend Yield: 0.12%, EPS: ₹37.72, Book Value: ₹313.6, Debt-to-Equity: 0.28, and Current Ratio: N/A. The company's market cap stands at ₹57,520.99 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Glenmark Pharmaceuticals Ltd stock opened at ₹2,140 and is currently trading at ₹2,225.8, showing a gain of ₹108.20 (5.11%). The intraday high is ₹2,240 and low is ₹2,130.4. The trading volume stands at 15,54,898 shares, indicating strong market participation today.
Glenmark Pharmaceuticals Ltd has a Price-to-Earnings (P/E) ratio of 53.82, which means investors are willing to pay ₹53.82 for every ₹1 of earnings. With an EPS of ₹37.72, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Glenmark Pharmaceuticals Ltd has a market capitalization of ₹57,520.99 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹2,225.8) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Glenmark Pharmaceuticals Ltd has a book value of ₹313.6 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹2,225.8, which is 609.8% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Glenmark Pharmaceuticals Ltd has a Return on Equity (ROE) of 6.67% and Return on Capital Employed (ROCE) of 19.40%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Glenmark Pharmaceuticals Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Glenmark Pharmaceuticals Ltd has a debt-to-equity ratio of 0.28, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Glenmark Pharmaceuticals Ltd has an Earnings Per Share (EPS) of ₹37.72, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹2,225.8 and P/E ratio of 53.82, investors are paying 53.82 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Glenmark Pharmaceuticals Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Glenmark Pharmaceuticals Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Glenmark Pharmaceuticals Ltd stock, consider: 1) Fundamental Analysis - Review P/E (53.82), ROE (6.67%), debt-to-equity (0.28), and growth rates. 2) Technical Analysis - Check 52-week range (₹1336.00 - ₹2284.80), moving averages, and chart patterns. 3) Valuation - Compare current price (₹2225.80) with book value (₹313.60) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Glenmark Pharmaceuticals Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹2,225.8 is 222480x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Glenmark Pharmaceuticals Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1336.00 - ₹2284.80). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.28 indicates leverage. 4) Liquidity Risk - Based on trading volume of 15,54,898 shares. 5) Valuation Risk - P/E of 53.82 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Glenmark Pharmaceuticals Ltd operates in the industry with key metrics: P/E ratio of 53.82, ROE of 6.67%, market cap of ₹57,520.99 crores, and dividend yield of 0.12%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.28), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Glenmark Pharmaceuticals Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹2,225.8, with a 52-week range of ₹1336.00 to ₹2284.80. Based on fundamentals like P/E (53.82), ROE (6.67%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Glenmark Pharmaceuticals Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹2225.80. 2) Fundamental Deterioration - Declining ROE (currently 6.67%), increasing debt (D/E: 0.28), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Glenmark Pharmaceuticals Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.12%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu